Fidia S.p.A. (BIT:FDA)
Italy
· Delayed Price · Currency is EUR 0.3993
-0.0199 (-4.75%)
Jun 27, 2025, 5:35 PM CET
Fidia Revenue
In the year 2024, Fidia had annual revenue of 17.53M EUR, down -38.98%. Fidia had revenue of 8.11M in the half year ending December 31, 2024, a decrease of -46.72%.
Revenue
17.53M
Revenue Growth
-38.98%
P/S Ratio
0.17
Revenue / Employee
110.28K
Employees
159
Market Cap
2.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Leonardo S.p.a. | 18.26B |
| Poste Italiane | 13.64B |
| Prysmian | 18.18B |
| Fincantieri | 7.95B |
| Iveco Group | 14.95B |
| Interpump Group | 2.05B |
| Maire | 6.32B |
| Webuild | 11.03B |
Fidia News
- 23 hours ago - Granules India clears US FDA Pre-Approval Inspection with zero observations - Business Upturn
- 1 day ago - FDA expanding COVID vaccine warnings over rare heart side effect - The Hill
- 1 day ago - Ultragenyx gets breakthrough therapy status from FDA for GTX-102 - Seeking Alpha
- 1 day ago - Bristol Myers wins favorable FDA label updates for cell therapies Breyanzi and Abecma - Seeking Alpha
- 2 days ago - U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels - Benzinga
- 2 days ago - Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide - Seeking Alpha
- 2 days ago - No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall - Benzinga
- 2 days ago - Rally to raise awareness against drug usage held - The Times of India